Cancer Immunotherapy Market is expected to reach US$ 261.74 billion by 2033 | Major players - Merck & Co., Inc., AstraZeneca, Pfizer Inc., Novartis AG.

Market Size and Growth:

The Global Cancer Immunotherapy Market Size reached US$ 137.70 billion in 2024 and is expected to reach US$ 261.74 billion by 2033, growing at a CAGR of 7.9% during the forecast period 2025-2033. The Market is growing due to increasing cancer prevalence, rising adoption of advanced immunotherapies, and continuous innovations in treatment options. According to DataM Intelligence Report.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/cancer-immunotherapy-market?sz

The Cancer Immunotherapy Market involves the development, production, and commercialization of therapies that stimulate or enhance the body's immune system to target and destroy cancer cells. It includes immune checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and CAR-T cell therapies, aiming to provide effective, targeted, and personalized treatment options with reduced side effects compared to traditional cancer therapies.

United States: Recent Developments of Cancer Immunotherapy Market

✅ September 2025: The FDA granted breakthrough therapy designation to olomorasib combined with pembrolizumab (Keytruda) for cancer treatment, advancing combination immunotherapy approaches.

✅ October 2025: There were multiple FDA approvals and designations expanding treatment options with immune checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies.

✅ November 2025: The U.S. cancer immunotherapy drug market has expanded rapidly with strong R&D pipelines and innovations in immunomodulators and cancer vaccines, with a focus on lung cancer immunotherapy ongoing clinical trials and combination regimens.

Europe: Recent Developments of Cancer Immunotherapy Market

✅ September 2025: EMA's CHMP endorsed inavolisib for PIK3CA-mutated ER-positive breast cancer after showing a 57% reduction in progression risk.

✅ October 2025: Bayer secured EU approval for darolutamide plus androgen-deprivation therapy for metastatic hormone-sensitive prostate cancer.

✅ November 2025: Europe continues to lead in immunotherapy innovation with companies like Roche and AstraZeneca driving advancements, supported by increasing R&D activities and government funding like the EU's Horizon health programs.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cancer-immunotherapy-market?sz

Recent FDA / Regulatory Approvals in 2025:

✅ Enfortumab vedotin (Padcev) + Pembrolizumab (Keytruda) - approved by U.S. Food and Drug Administration (FDA) (Nov 21, 2025) as neoadjuvant + adjuvant therapy for adults with muscle‐invasive bladder cancer (MIBC) who are ineligible for cisplatin. This perioperative combo reduced the risk of recurrence/progression/death by ~60% and death risk by ~50% vs surgery alone.

✅ Durvalumab (Imfinzi) plus FLOT chemotherapy - approved in November 2025 for patients with resectable gastric or gastroesophageal junction adenocarcinoma. This marks the first immunotherapy/chemo approval in that perioperative gastric/GEJ cancer setting.

✅ Beyond those, regulatory momentum in 2025 remains strong: earlier in the year, combinations such as Pembrolizumab + trastuzumab + chemotherapy for HER2‐positive gastric/GEJ cancers, and dual‐checkpoint regimens for MSI-H/dMMR colorectal cancer had already reshaped standards of care.

Mergers & Acquisitions / Corporate Moves in 2025:

✅ Genmab A/S announced acquisition of Merus N.V. for about US$8.0 billion (all-cash, $97/share) - deal expected to close around Q1 2026. The acquisition brings Merus' late‐stage oncology assets (notably the bispecific antibody Petosemtamab, in Phase 3) into Genmab's pipeline.

✅ This deal underscores continuing consolidation: big biotechs are acquiring clinical‐stage immuno-oncology firms to bolster their pipelines - particularly with bispecific antibody, multispecific antibody, and next-gen immunotherapy platforms.

Major Players:

Key companies in the Cancer Immunotherapy market include:

Merck & Co., Inc.
Johnson & Johnson Services, Inc.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
F. Hoffmann-La Roche Ltd
Novartis AG
Kite Pharma, Inc.
Dendreon Pharmaceuticals LLC.
Amgen Inc.

Segments Covered in the Cancer Immunotherapy Market:

By Type: Immune Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Therapy, Other Immunotherapies.

By Indication: Non-Small Cell Lung Cancer (NSCLC), Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Breast Cancer, Bladder Cancer, Others.

Regional Analysis for Cancer Immunotherapy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=cancer-immunotherapy-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Cancer Immunotherapy market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Cancer Immunotherapy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Cancer Immunotherapy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Cancer Immunotherapy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Cancer Immunotherapy market?

➠ Who are the global key manufacturers of the Cancer Immunotherapy Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Cancer Immunotherapy market opportunities and threats faced by the vendors in the global Cancer Immunotherapy Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Cancer Immunotherapy market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.